remdesivir
present
lead
drug
candid
treatment
ebov
infect
chemic
attribut
extend
phosphoramid
equip
cn
group
galidesivir
also
would
happen
would
also
contain
cn
group
would
convert
phosphoramid
prodrug
favipiravir
effect
free
yellow
fever
viru
infect
less
punta
toro
viru
would
happen
would
convert
furthermor
extend
phosphoramid
entiti
also
forgotten
could
convert
phosphoramid
eicar
contain
ethynyl
reminisc
cyano
group
could
first
transform
convert
phosphoramid
scheme
chemic
intervent
may
provid
potenti
clue
design
new
medicin
ebov
hfv
infect
candid
antivir
compound
current
avail
treatment
ebov
hfv
infect
galidesivir
remdesivir
ribavirin
eicar
pyrazofurin
favipiravir
box
scheme
attempt
increas
efficaci
potenti
lower
toxic
could
applic
first
convert
subsequ
phosphoramid
scheme
remdesivir
addit
also
contain
cyanogroup
manipul
alreadi
achiev
author
declar
conflict
interest
erik
de
clercq
emeritu
professor
ku
leuven
belgium
sinc
present
teach
cours
chemistri
servic
medicin
faculti
scienc
univers
south
bohemia
czech
republ
joint
program
keppler
univers
linz
austria
receiv
jointli
dr
anthoni
fauci
dr
paul
janssen
award
biomed
research
co
discov
number
antivir
drug
current
use
treatment
hsv
valaciclovir
vzv
brivudin
cmv
cidofovir
hbv
adefovir
dipivoxil
tenofovir
disoproxil
fumar
tdf
tenofovir
alafenamid
taf
hiv
infect
tdf
taf
combin
tdf
emtricitabin
truvada
approv
worldwid
prophylaxi
prep
hiv
infect
